FDA wants more views on OTC monograph fees

9 August 2016 - Deborah Wilkes


The US Food and Drug Administration (FDA) is seeking further comments on a potential user-fee programme for OTC monograph drugs. The regulatory agency is also running a webinar to update stakeholders on its talks with the Consumer Healthcare Products Association (CHPA).

Click tags below for more information on topics:

FDA CHPA OTC Monograph System

Annual Subscription Holder?

Sign in to continue reading.

Sign In

Back to Industry News

Share this page: